Why the study?
Does IL-6 deficiency prevent norepinephrine-induced left ventricular hypertrophy in mice?
Does IL-6 deficiency prevent norepinephrine-induced left ventricular hypertrophy in mice?
Interleukin-6 plays a crucial mechanistic role in the development of norepinephrine-induced left ventricular hypertrophy and extracellular matrix remodeling in mice.
Answers are grounded in this paper and cite their sources.
IL-6 may mediate norepinephrine-induced LV hypertrophy in mice; leaves open whether IL-6 inhibition prevents remodeling in humans.
BACKGROUND: Elevated serum concentration of interleukin (IL)-6 is a predictor for poor prognosis in congestive heart failure. It was shown previously in rats, that IL-6 expression in the left ventricle (LV) was followed by LV hypertrophy. METHODS: Using IL-6 deficient mice (IL-6(-/-)), we studied the role of IL-6 in a model of norepinephrine (NE)-induced LV hypertrophy. RESULTS: In wild type (WT) mice, IL-6 mRNA expression and its concentration in the serum were elevated after 4 h of NE-treatment (s.c. 0.25 mg.h)./kg Further, NE-induced LV hypertrophy was detected: LV weight/body weight (LVW/BW) ratio (+12.3+/-3%, p < 0.05) and mRNA expression of atrial natriuretic peptide (ANP) in WT mice (+120+/-25%, p < 0.05) after 3 days were increased. In contrast, NE did not induce elevation of LVW/BW ratio and ANP expression in IL-6(-/-) mice. Replacement with recombinant IL-6 restored the hypertrophy-inducing effect of NE in IL-6(-/-) mice. As to the extracellular matrix (ECM) proteins, NE increased collagen type I and III expression only in WT mice and not in IL-6(-/-) mice. The addition of recombinant IL-6 elevated the expression of the ECM proteins to the WT level. CONCLUSION: IL-6 is a major player in the development of NE-induced LV hypertrophy in mice.
No takes yet. Share an insight, caveat, or question.
Meier et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: